Eli Lilly and Company (LLY)vsSo-Young International Inc (SY)
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
SY
So-Young International Inc
$1.94
-8.06%
HEALTHCARE · Cap: $206.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 5112% more annual revenue ($86.46B vs $1.66B). LLY leads profitability with a 31.9% profit margin vs -15.6%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
SY
Hold44
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Reasonable price relative to book value
Revenue surging 45.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Smaller company, higher risk/reward
ROE of -17.2% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : SY
The primary concerns for SY are Market Cap, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while SY is a hypergrowth play — different risk/reward profiles.
SY carries more volatility with a beta of 2.20 — expect wider price swings.
SY is growing revenue faster at 45.6% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 44/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?